Canadian Court Upholds Lipitor Patent

Law360, New York (March 21, 2008, 12:00 AM EDT) -- After a series of unfavorable rulings for Pfizer Inc., a Canadian appeals court has upheld the pharmaceutical giant's patent for Lipitor, delivering a setback to Ranbaxy Laboratories Ltd. in its quest to market a generic version of the blockbuster cholesterol drug.

The Federal Court of Appeal of Canada ruled Thursday that Ranbaxy's lower-priced knockoff would not be entitled to regulatory approval until Pfizer's patent expires in July 2010, according to Pfizer.

“This decision sends a strong signal about the importance of protecting intellectual property in Canada,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.